Syensqo

Syensqo in-cosmetics 2026 press kit

At in-cosmetics 2026, Syensqo will be unveiling new hair and skin care solutions, including an advanced biotech peptide and a novel ceramide delivery technology.

Syensqo strengthens its commitment to responsible, high-performance beauty innovations at in-cosmetics® Global 2026

Syensqo is accelerating the shift toward responsible beauty at in-cosmetics® Global 2026, expanding its skin and hair care portfolio with science-driven solutions designed for both performance and sustainability. These developments reflect the company’s continued investment in advanced formulation expertise, including its first step into scalp care.

Syensqo unveils AI-designed, bio-sourced innovation to advance scalp care

Syensqo announced today the launch of Re2 Coffea Arabica Peptide, a new scalp care active developed by Bota Biosciences. This achievement reflects the strength of the strategic partnership established between the two companies in 2025 and highlights their shared ambition to bring breakthrough, science-driven solutions to the personal care market.

Reader enquiries

Syensqo
Rue de la Fusée 98
1130 Brussels
Belgium

www.syensqo.com/en

@Syensqo

syensqo/

Syensqo/

channel/UC2llMaHNTklvl8N4gwSiuRw


Notes for editors

About Syensqo

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.

Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and healthcare applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Learn more at www.syensqo.com.

Related images

 

 

Editorial enquiries

Kim LommaertKim Lommaert
EMG

+31 164 317 021

klommaert@​emg-marcom.com

 

Share

 

More news from